- Research article
- Open Access
EVI1activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22)
BMC Cancer volume 8, Article number: 193 (2008)
Variant translocations t(9;22) occur in 5 to 10% of newly diagnosed CMLs and additional genetic changes are present in 60–80% of patients in blast crisis (BC). Here, we report on a CML patient in blast crisis presenting with a four-way variant t(9;22) rearrangement involving the EVI1 locus.
Dual-colour Fluorescence In Situ Hybridisation was performed to unravel the different cytogenetic aberrations. Expression levels of EVI1 and BCR/ABL1 were investigated using real-time quantitative RT-PCR.
In this paper we identified a patient with a complex 4-way t(3;9;17;22) which, in addition to BCR/ABL1 gene fusion, also resulted in EVI1 rearrangement and overexpression.
This report illustrates how a variant t(9;22) translocation can specifically target a second oncogene most likely contributing to the more aggressive phenotype of the disease. Molecular analysis of such variants is thus warranted to understand the phenotypic consequences and to open the way for combined molecular therapies in order to tackle the secondary oncogenic effect which is unresponsive to imatinib treatment.
Chronic myeloid leukemia (CML) has a typical indolent chronic phase that may last several years but will ultimately progress into acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL). The typical associated translocation t(9;22)(q34;q11), leading to the BCR/ABL1 fusion gene and constitutive activation of the ABL1 tyrosine kinase on 9q34, is considered to be the initial transforming event . Instead of the classical t(9;22) translocation, cryptic and variant translocations occur in about 5 to 10 % of all CML cases. CML in blast crisis is often accompanied by the presence of additional chromosome aberrations . Amongst those, activation of the EVI1 gene has been reported in a small percentage of patients . Ectopic expression of the EVI1 gene is usually due to recurrent 3q26 translocations such as the t(3;21)(q26;q22) (AML1/EVI1) and the inv(3;3)(q21q26). Transcriptional activation of EVI1 can also occur in the absence of genomic rearrangement at this locus . In general, EVI1 upregulation confers a poor prognosis in hematological malignancies .
In this study, we describe how the molecular characterization of the translocation breakpoints of a variant t(9;22) in a patient with CML in blast crisis lead to the discovery of involvement of the EVI1 locus. We also discuss the importance of the study of secondary genomic events present or occurring during blast crisis with respect to the development of strategies for treatment of CML patients in blast crisis.
A diagnostic bone marrow sample was obtained from a patient who presented with features of chronic myeloid leukemia in blast crisis. The patient died nine months after diagnosis.
This study was approved by the Ethical Committee of the Ghent University Hospital (2003/273).
Cytogenetic analysis of the diagnostic bone marrow sample was performed according to standard methods. A 24-hour bone marrow culture was performed and chromosomes were G-banded with a trypsin-Giemsa stain (GTG-banding). Fifteen metaphases were analyzed and the karyotype was described according to the International System for Human Cytogenetic Nomenclature .
Fluorescence in situ hybridisation analyses
Dual-colour Fluorescence In Situ Hybridisation (FISH) was performed on the diagnostic bone marrow sample using a t(9;22) specific BCR/ABL1 dual color, dual fusion probe (Abbott Vysis, Germany). Commercial Whole Chromosome Paints (WCP) for chromosomes 3, 9, 17 and 22 (Metasystems, Germany) were used to unravel the translocations in the bone marrow sample. A commercial centromeric probe for chromosome 3 (Abbott Vysis, Germany) was used to facilitate identification of chromosome 3.
Detection of EVI1 rearrangement was done using the following BAC clones: RP11-694D5 (position 169.8 Mb, centromeric of EVI1), RP11-82C9 (position 170.3 Mb, EVI1 overlapping) and RP11-362K14 (position 171.1 Mb, telomeric of EVI1) (NCBI genome browser Build 36.1). All non-commercial clones were acquired from the Sanger Wellcome Trust Institute, Hinxton, Cambridge (United Kingdom). The EVI1 specific probes were labelled with biotin-16-dUTP (Roche Diagnostics, Belgium) and digoxigenin-12-dUTP (Roche Diagnostics, Belgium) and FISH analysis was performed as previously described [7, 8]. Biotin labelled probes were detected with Fluorescein IsoThioCyanate (FITC)-conjugated anti-biotin antibodies (Invitrogen, Belgium) and digoxigenin labelled probes with TetramethylRhodamine IsoThioCyanate (TRITC)-conjugated anti-digoxigenin antibodies (Roche Diagnostics, Belgium). A minimum of 100 nuclei and a minimum of 5 metaphases were scored using a fluorescence microscope (Axioplan 2, Zeiss, Belgium) and images were captured using a black and white CCD camera and images were processed with the ISIS software program (MetaSystems, Germany).
Real-time quantitative RT-PCR
Total RNA was extracted from the diagnostic bone marrow sample using the Trizol LS reagent (Invitrogen, Belgium) according to the manufacturer's recommendations. cDNA was prepared from 2 μg of total RNA with the iScript cDNA Synthesis Kit (Bio-Rad, Belgium) according to the manufacturer's instructions.
Real-time quantitative RT-PCR (qRT-PCR) for the EVI1 (forward: 5'-GTACTTGAGCCAGCTTCCAACA-3', reverse: 5'-CTTCTTGACTAAAGCCCTTGGA-3', exon 1b-2), cEVI1 (forward: 5'-ACCCACTCCTTTCTTTATGGACC-3', reverse: 5'-TGATCAGGCAGTTGGAATTGTG-3', exon 8–9), MDS1/EVI1 (forward: 5'-GAAAGACCCCAGTTATGGATGG-3', reverse: 5'-GTACTTGAGCCAGCTTCCAACA-3', exon 2 MDS1 – exon 2 EVI1) and MDS1 (forward: 5'-GAAAGACCCCAGTTATGGATGG-3', reverse: 5'-TCTCTTCCCCAAATACAACCAAG-3', exon 2–3) transcripts was performed as previously described [9, 10]. Cell line K562 was used as a positive control and reference, its EVI1 expression level was set to 1.
QRT-PCR for the BCR/ABL1 fusion transcript was done according to the Europe Against Cancer program (EAC) protocol .
Detailed cytogenetic analysis of 15 G-banded metaphases from the diagnostic bone marrow revealed the following karyotype: 50, XY, add(3)(q26),+8, add(9)(q34),+add(9)(q34),+10,+12, del(16)(q23),-17, der(22)t(9;22)(q34;q11),+mar [cp15] (Fig. 1).
FISH with the BCR/ABL1 dual-color dual-fusion probe revealed two fusion signals together with a single green and red signal in interphase nuclei. In metaphases, one fusion was located on the Philadelphia chromosome whereas the second fusion signal was present on the marker chromosome instead of on the der(9)t(9;22)(q34;q11.2) (Fig. 2A). Real-time quantitative RT-PCR (qRT-PCR) confirmed the presence of the BCR/ABL1 fusion and revealed a major MBCR transcript (data not shown).
Further FISH characterisation of this t(9;22) variant translocation, revealed involvement of chromosomes 3 and 17. FISH analysis with two probe combinations for the EVI1 locus (EVI1 centromeric and overlapping; EVI1 telomeric and overlapping) revealed a breakpoint 5' and telomeric of EVI1 and translocation of the telomeric chromosome 3 segment to the der(9) (Fig. 2B). The translocation of the ABL1/BCR segment from the der(9) to the der(17) was accompanied by translocation of the distal 17q segment immediately distal to the EVI1 locus on the der(3). FISH with whole chromosome paints confirmed these observations (Fig. 2C–D).
Based on these FISH analyses, the karyotype was revised as 50, XY, der(3)(3pter→q26::17q22→qter),+8, der(9)(9pter→q34::3q26→qter),+der(9)(9pter→q34::3q26→qter),+10,+12, del(16)(q23), der(17)(17pter→q22::9q34q34::22q11→qter), der(22)(22pter→q11::9q34→qter) [cp15].
Ectopic expression of the full length EVI1 transcript was detected with qRT-PCR using the 5' located EVI1 primer pair (Fig. 3A). qRT-PCR with the 3' located cEVI1 primer pair was able to detect additional ectopic expression 5' EVI1 variant transcripts (Fig. 3B). No expression of the MDS1/EVI1 or MDS1 transcripts could be detected with qRT-PCR (data not shown).
We describe the molecular characterization of a complex 4-way t(3;9;17;22) translocation, which in addition to BCR-ABL1 gene fusion also resulted in EVI1 overexpression. Based on FISH and karyotype data we propose a two-step mechanism  for generating the complex 4-way translocation, i.e. first the formation of a classical t(9;22), followed by a subsequent three-way translocation involving chromosomes 3, 17 and the derivative chromosome 9. The latter rearrangement was the result of translocation of the ABL1/BCR segment from the der(9) to chromosome 17, translocation of the distal 17q segment to the 3q26 locus on chromosome 3 and translocation of the distal part of chromosome 3 to the der(9). Further molecular investigation using FISH indicated that the 3q26 breakpoint located immediately distal of the 5' end of the EVI1 locus. As expected qRT-PCR revealed ectopic expression of EVI1. A third and final step encompassed the duplication of the der(9) in this patient (Fig. 4A–C).
EVI1 overexpression is a well established unfavourable prognostic marker in AML patients, and is often found in progressive or blast crisis CML [4, 13, 14]. It is therefore likely that, like for the additional alterations such as trisomy 8 and isochromosome 17q, the observed EVI1 overexpression contributes to the aggressive phenotype of the blastic CML phase. The presence of the additional cytogenetic abnormality del(16)(q23) in this patient could also negatively influence disease progression.
Apart from the known recurrent secondary changes occurring during progression or blast phase in CML, most additional rearrangement breakpoints have remained unexplored at the molecular level. It can be assumed that such breakpoints target specific genes leading to additional proliferative or survival advantage to the tumour cell. The present study illustrates the importance of characterization of such secondary rearrangements or breakpoints in order to understand the molecular basis of the acute phase in CML.
Given the progress in CML treatment due to the development of 1st and 2nd generation small molecules (TK-inhibitors) such as imatinib, nilotinib and dasatinib , targeting of such additional oncogenic events now represents a new challenge for future CML treatment. Even though currently the number of targeted therapies is still limited, it can be anticipated that in the future, combination therapies with imatinib and compounds targeted at the secondary changes can become a reality. Therefore, we propose a systematic testing of 3q26 aberrations in CML patients in blast crisis or CML patients with an evolutionary disease course. Since to date only a few target genes of the transcriptional repressor EVI1 are known , further research will be needed to identify more genes implicated in EVI1 pathogenesis thus opening the way for development of novel targeted therapeutics.
In conclusion, we report on a CML patient in blast crisis presenting with a three-step variant Ph-positive chromosome rearrangement, involving the EVI1 locus. This report shows that the variant translocation can specifically target a second oncogene which most likely contributes to the more aggressive phenotype of the leukemia. Molecular analysis of t(9;22) variants is needed to understand its phenotypic consequences and to open the way to combined molecular therapies in order to counteract the secondary oncogenic effect which is unresponsive to imatinib treatment.
- ABL1 :
ABeLson murine leukemia viral oncogene homolog 1
Acute Lymfoid Leukemia
Acute Myeloid Leukemia
Breakpoint Cluster Region
Chronic Myeloid Leukemia
Europe Against Cancer
- EVI1 :
Ecotropic Viral Integration site 1
Fluorescence In Situ Hybridisation
- MDS1 :
MyeloDysplasia Syndrome 1
Quantitative Reverse Transcription Polymerase Chain Reaction
Whole Chromosome Paint.
Goldman JM, Melo JV: Chronic myeloid leukemia – advances in biology and new approaches to treatment. The New England journal of medicine. 2003, 349 (15): 1451-1464. 10.1056/NEJMra020777.
Johansson B, Fioretos T, Mitelman F: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta haematologica. 2002, 107 (2): 76-94. 10.1159/000046636.
Ogawa S, Kurokawa M, Tanaka T, Tanaka K, Hangaishi A, Mitani K, Kamada N, Yazaki Y, Hirai H: Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia. 1996, 10 (5): 788-794.
Lugthart S, Drunen EV, Norden YV, Hoven AV, Erpelinck CA, Valk PJ, Beverloo HB, Lowenberg B, Delwel R: High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008
Buonamici S, Chakraborty S, Senyuk V, Nucifora G: The role of EVI1 in normal and leukemic cells. Blood cells, molecules & diseases. 2003, 31 (2): 206-212. 10.1016/S1079-9796(03)00159-1.
Shaffer L, Tommerup N, (eds): ISCN 2005: an international system for human cytogenetic nomenclature. 2005, Basel: S. Karger
Van Limbergen H, Poppe B, Michaux L, Herens C, Brown J, Noens L, Berneman Z, De Bock R, De Paepe A, Speleman F: Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. Genes, chromosomes & cancer. 2002, 33 (1): 60-72. 10.1002/gcc.1212.
Van Roy N, Vandesompele J, Berx G, Staes K, Van Gele M, De Smet E, De Paepe A, Laureys G, Drift van der P, Versteeg R, et al: Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between the ACCN1 and TLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients. Genes, chromosomes & cancer. 2002, 35 (2): 113-120. 10.1002/gcc.10034.
Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, De Paepe A, Cervera J, Recher C, De Mas V, et al: EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes, chromosomes & cancer. 2006, 45 (4): 349-356. 10.1002/gcc.20295.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome biology. 2002, 3 (7): 1-11. 10.1186/gb-2002-3-7-research0034.
Gabert J, Beillard E, Velden van der VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, et al: Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia. 2003, 17 (12): 2318-2357. 10.1038/sj.leu.2403135.
Gorusu M, Benn P, Li Z, Fang M: On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer genetics and cytogenetics. 2007, 173 (2): 97-106. 10.1016/j.cancergencyto.2006.10.006.
Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, Poel-van de Luytgaarde van der S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, et al: High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003, 101 (3): 837-845. 10.1182/blood-2002-05-1459.
Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, et al: Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer. 2008, 47 (4): 288-298. 10.1002/gcc.20532.
Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM: Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008, 8 (1): 99-110. 10.1586/14737126.96.36.199.
Wieser R: The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene. 2007, 396 (2): 346-357. 10.1016/j.gene.2007.04.012.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/193/prepub
ADW was supported by a grant from the BOF foundation, Belgium (grant nr. 01D28905). BP and BV are senior clinical investigators with the Research Foundation – Flanders (FWO-Vlaanderen). This study is supported by the FWO-Vlaanderen, grant nr. G.0106.05 and by the GOA- BOF foundation, Belgium (grant nr. 12051203). This text presents research results of the Belgian Program of Interuniversity Poles of Attraction initiated by the Belgian State, Prime Minister's Office, Science policy Programming. The scientific responsibility is assumed by the authors.
The authors declare that they have no competing interests.
ADW carried out the genetic studies and drafted the manuscript. AC is the patients referring physician. BC helped with EVI1 expression analysis, JD performed the blood cell counts, BV analyzed the BCR-ABL1 expressions and JP performed the immunophenotyping. BP, NVR and FS helped to draft the manuscript.
About this article
Cite this article
De Weer, A., Poppe, B., Cauwelier, B. et al. EVI1activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22). BMC Cancer 8, 193 (2008). https://doi.org/10.1186/1471-2407-8-193
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Chronic Myeloid Leukemia Patient